Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovascular glaucoma prevention by intravitreal aflibercept in proton therapy for large choroidal melanoma
2016-003329-40Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jan 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in choroidal melanoma and neovascular glaucoma (NVG) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Neovascular glaucoma occurrence at 5 years. Started Jan 2017; status: active.
02
Drugs
aflibercept
03
Conditions
choroidal melanomaneovascular glaucoma (NVG)
Beyond the preview
Go deeper on 2016-003329-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003329-40.